A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3004-3007

  Ault, Kevin A ^a   Giuliano, Anna R ^b   Edwards, Robert P ^c   Tamms, Gretchen ^d   Kim, Lee Lian ^d   Smith, Judith F ^d   Jansen, Kathrin U ^d   Allende, Maria ^d   Taddeo, Frank J ^d   Skulsky, DeeMarie ^d   Barr, Eliav ^d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Human papilloma virus; Serology; Vaccination

Indexed keywords

UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONDYLOMA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GEOMETRY; HUMAN; IMMUNOGENICITY; INCIDENCE; MEDICAL ASSESSMENT; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; VIRAL VACCINES;

EID: 3843151595     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.020     Document Type: Conference Paper

References (10)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102:1997;3-8
2. Madeleine M., Daling J., Schwartz S., et al. Human papilloma virus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol. Biomarkers Prev. 10:2001;171-177
3. Liu S., Semenciw R., Probert A., Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer. 11:2001;24-31
4. Evans T., Bonnez W., Rose R., et al. A phase I study of a recombinant virus-like particle against human papilloma virus type 11 in healthy adult volunteers. J. Infect. Dis. 183:2001;1485-1493
5. Koutsky L., Ault K., Wheeler C., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:2002;1645-1651
6. Harro C., Pang Y., Roden R., et al. Safety and immunogenicity trial of adult volunteers of a human papilloma virus 16 L1 virus-like particle vaccine. JNCI. 93:2001;284-292
7. Brown D.R., Bryan J.T., Schroeder J.M., et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect. Dis. 184:2001;1183-1186
8. Sigurdsson K. Effect of organized screening on the risk of cervical cancer: evaluation of screening activity in Iceland 1964-1991. Int. J. Cancer. 54:1993;563-570
9. Ponten J., Adami H.-O., Bergstrom R., et al. Strategies for the global control of cancer. Int. J. Cancer. 60:1995;1-26
10. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6):2003;518-527